Sano, Kaori http://orcid.org/0000-0002-4887-1302
Bhavsar, Disha http://orcid.org/0000-0003-1564-3298
Singh, Gagandeep http://orcid.org/0000-0001-5848-2741
Floda, Daniel
Srivastava, Komal
Gleason, Charles
Amoako, Angela A.
Andre, Dalles
Beach, Katherine F.
Bermúdez-González, Maria C.
Cai, Gianna
Cognigni, Christian
Kawabata, Hisaaki
Kleiner, Giulio
Lyttle, Neko
Mendez, Wanni
Mulder, Lubbertus C. F.
Oostenink, Annika
Raskin, Ariel
Rooker, Aria
Russo, Kayla T.
Salimbangon, Ashley Beathrese T.
Saksena, Miti
Sominsky, Levy A.
Tcheou, Johnstone
Wajnberg, Ania
Carreño, Juan Manuel
Simon, Viviana http://orcid.org/0000-0002-6416-5096
Krammer, Florian http://orcid.org/0000-0003-4121-776X
,
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (75N93019C00051)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (75N91019D00024)
Article History
Received: 3 December 2021
Accepted: 25 July 2022
First Online: 1 September 2022
Competing interests
: The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which list F.K. as co-inventor. V.S. is also listed on the serological assay patent application as co-inventor. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. F.K. has consulted for Merck and Pfizer (before 2020) and is currently consulting for Pfizer, Seqirus, Third Rock Ventures, and Avimex. The Krammer laboratory is also collaborating with Pfizer on animal models of SARS-CoV-2. The remaining authors declare no competing interests.